---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-028863"
form_type: "8-K"
ticker: "AIXC"
cik: "0001460702"
company_name: "AIxCrypto Holdings, Inc."
filed_at: "2023-08-15T23:59:59+00:00"
generated_at: "2026-06-11T09:23:12.750583+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Qualigen sells FastPack for ~$5M; Q2 loss narrows to $3.5M; FDA OK for QN-302 trial

## Summary
- Divested FastPack diagnostics to Chembio (BIOSYNEX) for ~$5M all cash; proceeds for therapeutics pipeline.
- FDA cleared IND for QN-302; Phase 1 trial in advanced solid tumors to start H2 2023, targeting 24+ patients in 2024.
- Q2 revenue $1.6M (+14% YoY); net loss $3.5M ($0.69/share) vs $4.1M ($1.12) in prior-year quarter.
- R&D spend $1.3M (89% on therapeutics); Pan-RAS platform on track for late in vivo candidate by year-end.

## SEC filing metadata
- accession: 0001493152-23-028863
- form_type: 8-K
- ticker: AIXC
- cik: 0001460702
- company_name: AIxCrypto Holdings, Inc.
- filed_at: 2023-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460702/000149315223028863/0001493152-23-028863-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460702/000149315223028863/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-028863
- JSON: https://secwatch.observer/filing/0001493152-23-028863.json
- Plain text: https://secwatch.observer/filing/0001493152-23-028863.txt

## Key facts
- Earnings Releases
  AIxCrypto Holdings, Inc. reported the quarter ended June 30, 2023 results: revenue approximately $1.6 million.
  - Period: the quarter ended June 30, 2023
  - Revenue: approximately $1.6 million
  - Result: reported results
  source text: Revenues from product sales for the quarter ended June 30, 2023 were approximately $1.6 million compared to approximately $1.4 million for the same period of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460702/000149315223028863/0001493152-23-028863-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.